Company Encyclopedia
View More
name
Pcr Gbl Cash Cows Dvd
GCOW.US
News
View More

Mirabella Financial Services LLP Has $2.41 Million Position in AbbVie Inc. $ABBV

Mirabella Financial Services LLP reduced its stake in AbbVie Inc. by 69.5% in Q2, owning 12,919 shares worth $2.41 million. Other institutional investors adjusted their positions in AbbVie. Analysts have varied ratings, with a consensus of "Moderate Buy" and a target price of $241.85. AbbVie reported Q3 earnings of $1.86 EPS, beating estimates, and increased its dividend to $1.73 per share. The stock opened at $228.68, with a market cap of $404.17 billion.

Market Beat·
US
ABBV
-0.66%
Market Beat·
US
ABBV
-0.66%

Deutsche Bank Sticks to Their Hold Rating for Rio Tinto (RIO)

Deutsche Bank analyst Liam Fitzpatrick maintained a Hold rating on Rio Tinto with a price target of £53.00. Fitzpatrick, a 4-star analyst, has an average return of 9.3% and a 58.13% success rate. RBC Capital also rated Rio Tinto as Hold, while Barclays maintained a Buy rating. Fitzpatrick covers the Basic Materials sector, including stocks like Rio Tinto, Teck Resources, and Lundin Mining.

Tip Ranks·
UK
RIO
0.00%
US
RTPPF
0.00%
US
RIO
-0.74%
Tip Ranks·
UK
RIO
0.00%
US
RTPPF
0.00%
US
RIO
-0.74%

First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN

First Trust Advisors LP reduced its stake in Amgen Inc. by 3.8% in Q2, selling 21,347 shares. Amgen's stock opened at $340.16, with a market cap of $183.17 billion. The company reported Q3 earnings of $5.64 per share, beating estimates, and announced a quarterly dividend of $2.38. Insiders sold shares, including EVP Murdo Gordon and SVP Rachna Khosla.

Market Beat·
US
AMGN
-1.52%
Market Beat·
US
AMGN
-1.52%

AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.

PR Newswire·
US
ABBV
-0.66%
PR Newswire·
US
ABBV
-0.66%

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

marketscreener·
US
MRK
-1.35%
US
HALO
-2.64%
marketscreener·
US
MRK
-1.35%
US
HALO
-2.64%
© 2025 Longbridge｜Disclaimer